Prana Provides an Update on the Phase IIa Trial of PBT2

Australian biopharmaceutical company Prana Biotechnology announced an update on its Phase IIa clinical trial of PBT2 in patients with Alzheimer’s disease.

According to Prana, the Phase IIa trial is a double-blind, placebo-controlled safety and tolerability study of PBT2 in patients with mild forms of Alzheimer’s disease.

In addition to safety, the trial is investigating the effect of PBT2 on multiple cerebrospinal fluid and blood biomarkers that have been directly associated with the etiology of Alzheimer’s disease, the company said.

An independent data safety monitoring board has reviewed blinded data of more than 50 patients and confirmed that the trial is safe to continue per the original protocol, the company added.

There have been no treatment-related serious adverse events or withdrawals, and 30 patients have already completed the trial, according to the company.

The company said it expects to complete patient treatment by the end of the year.